Acarix ABACIXF 47 Days Inventory is 1,271.91 as of Mar. 2026, which is 46% below its 10-year median of 2,339.21. GuruFocus rates ACIXF with a GF Score™ of 47/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 786 Medical Devices & Instruments companies, Acarix AB ranks worse than 98.6% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Acarix AB's Average Total Inventories for the
three
months ended in Mar. 2026 was $0.68 Mil. Acarix AB's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.05 Mil.
Hence, Acarix AB's Days Inventory for the
three
months ended in Mar. 2026 was 1,271.91.
The historical rank and industry rank for Acarix AB's Days Inventory or its related term are showing as below:
ACIXF'
s Days Inventory Range Over the Past 10 Years
Min: 1344.66 Med: 2339.21 Max: 4185.77
Current: 1859.9
During the past 12 years, Acarix AB's highest Days Inventory was 4185.77. The lowest was 1344.66. And the median was 2339.21.
ACIXF's Days Inventory is ranked worse than 98.6% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 179.86
vs ACIXF: 1859.90
Acarix AB's Days Inventory
declined
from Mar. 2025 (1,820.72) to Mar. 2026 (1,271.91).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Acarix AB's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.07.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Acarix AB's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 2.63.
Acarix AB (OTCPK:ACIXF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Acarix AB's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Acarix AB's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Acarix AB Days Inventory Related Terms
Acarix AB Days Inventory Historical Data
* Premium members only.
The historical data trend for Acarix AB's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Acarix AB's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Days Inventory distribution charts can be found below:
* The bar in red indicates where Acarix AB's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acarix AB (ACIXF) has a Days Inventory of 1,271.91 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Acarix AB and its competitors. This is 46% below median its historical median of 2,339.21. Over the past decade, Acarix AB's Days Inventory has ranged from 1,344.66 to 4,185.77. According to the industry distribution chart, Acarix AB ranks #775 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 98.6%.
Is Acarix AB's Days Inventory too high?
Acarix AB's current Days Inventory of 1,271.91 is 46% below median its 10-year median of 2,339.21. Over the past 10 years, this metric has ranged from a low of 1,344.66 to a high of 4,185.77. The Medical Devices & Instruments industry median Days Inventory is 179.86. Acarix AB's value of 1,271.91 is 607.2% above this industry median. Based on the distribution chart, Acarix AB ranks #775 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Acarix AB has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Days Inventory compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #775 out of 786 companies for Days Inventory. This places Acarix AB in the lower half of its industry. The industry median Days Inventory is 179.86. Acarix AB's value of 1,271.91 is 607.2% above this benchmark. Historically, Acarix AB's own Days Inventory has ranged from 1,344.66 to 4,185.77 over the past decade. While the company's 10-year median is 2,339.21 vs. the industry median of 179.86, Acarix AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.86, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acarix AB's current Days Inventory of 1,271.91 is 607.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current Days Inventory is 1,271.91, which is 46% below median its own 10-year median of 2,339.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 45% above its estimated fair value. The current Days Inventory is 1,271.91, which is 46% below median its 10-year median of 2,339.21 and 607.2% above the Medical Devices & Instruments industry median of 179.86. Acarix AB's overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Days Inventory is 1,271.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of $0.03 is trading 45% above its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Significantly Overvalued.
Key valuation signals for ACIXF:
Days Inventory: 1,271.91 (46% below median its 10-year median of 2,339.21)
GF Value™: $0.02 vs. price of $0.03 (45% above fair value)
Industry Position: 607.2% above the Medical Devices & Instruments median (#775 of 786)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
47GF Score
Get the complete analysis for ACIXF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
